ADT has been shown to enhance the sensitivity of gliomas to radiotherapy both in vitro and in vivo (Hinrichs et al., 2018; Maletzki et al., 2017), particularly GBM cells with loss of p53 function (Hinrichs et al., 2018). Here, TP53 is linked to central nervous system cancer.